SB1518 (Pacritinib) | 2450

A potent JAK2/FLT3 inhibitor. Displays equipotent activity against JAK2 (I₅₀ = 23 nM) and FLT3 (IC₅₀ = 22 nM). SB1518 displays potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.

SB1518 (Pacritinib) is a potent JAK2/FLT3 inhibitor. Displays equipotent activity against JAK2 (IC₅₀ = 23 nM) and FLT3 (IC₅₀ = 22 nM).

2450 | SB1518 (Pacritinib) DataSheet

Alternate Name/Synonyms: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 937272-79-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₈H₃₂N₄O₃

Molecular Weight: 472.58

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent JAK2/FLT3 inhibitor

MDL Number: N/A

PubChem CID: 46216796

SMILES: C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC=CC(=C4)C5=NC(=NC=C5)NC(=C3)C=C2

InChi: InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

InChi Key: HWXVIOGONBBTBY-ONEGZZNKSA-N